- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06148467
Reverse Trigger Phenotypification and Response to Ventilatory Adjustments (RT-CHASERS)
Incidence of Reverse Trigger Phenotypes and Response to Ventilatory Adjustments in Patients With ARDS
The goal of this prospective observational study is to describe the incidence of reverse trigger (RT) in mechanically ventilated patients with diagnosis of acute respiratory distress syndrome (ARDS).
The main questions it aims to answer are:
- Real incidence of RT based on continuous monitoring
- The response to mechanical ventilatiory adjustments Participants will be included as soon as neuromuscular blockers (NMB)/sedation is stopped or in case of spontaneous respiratory efforts detection, whatever happens first. Continuous monitoring will be performed by esophageal manometry until switch to a pressure support (spontaneous) mode, restart of deep sedation/neuromuscular blockers by medical indication, or death.
In order to allow detection of possible RT in patients with ongoing sedation/NMB, mechanical ventilator waveforms will be screened every 1-2 hours by investigators and critical care physicians with at least 1 year of specific training in detection of dyssynchronies.
Study Overview
Status
Detailed Description
Measurements:
An esophageal catheter for manometry will be placed as usual practice with confirmation of adequate position with the Baydur's occlusion test before recordings. An independent flow sensor and pressure transducer will be placed and connected to a laptop computer to obtain real-time monitoring along with continuous recordings, which then will be off-line analyzed by two experts, for confirmation of RT and characterization.
Data collection:
Main cause of the acute respiratory failure and days on mechanical ventilation until enrollment will be collected as well as demographic characteristics, including APACHE II, SOFA and the previous requirement of prone positioning therapy.
At identification of the RT, drugs for sedation and analgesia, time from initiation of mechanical ventilation to RT identification and blood gas analysis will be recorded. Ventilatory settings will also be collected, including the control variable of the ventilatory mode (volume or pressure), respiratory rate, received tidal volume in ml/kg of predicted body weight, maximum inspiratory flow, ratio of partial arterial oxygen pressure (pO2) to fraction of inspired oxygen (FiO2), driving pressure and (positive end-expiratory pressure (PEEP). Data about esophageal pressure related to RT will also be recorded, including the magnitude of pressure swing, phase angle, coefficient of variation, RT phenotype, entrainment ratio and the presence of breath stacking.
Patient-centered outcomes including length of mechanical ventilation, intensive care and hospital length of stay, and mortality will be followed-up until 60 days.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Miguel Ibarra-Estrada, MD
- Phone Number: +523317593502
- Email: drmiguelibarra@hotmail.com
Study Locations
-
-
-
Guadalajara, Mexico, 44280
- Recruiting
- Hospital Civil Fray Antonio Alcalde
-
Contact:
- Miguel Ibarra-Estrada, MD
- Phone Number: 3317593502
- Email: drmiguelibarra@hotmail.com
-
Contact:
- Guadalupe Aguirre-Avalos, MD
- Email: guadalupe.aavalos@academicos.udg.mx
-
Sub-Investigator:
- Quetzalcóatl Chávez-Peña, MD
-
Sub-Investigator:
- Arnulfo López-Pulgarín, MD
-
Sub-Investigator:
- Guadalupe Aguirre-Avalos, PhD
-
Principal Investigator:
- Miguel Ibarra-Estrada, MD
-
Sub-Investigator:
- David Hernández-Lugo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of ARDS according to the Berlin criteria and added New Global Definition 2023
- Mechanical ventilation
Exclusion Criteria:
- <18 years
- Tracheostomy status
- Pneumothorax
- Tube thoracostomy with air leaks
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of reverse trigger
Time Frame: 60 days
|
Proportion of patients who developed reverse trigger
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days of mechanical ventilation
Time Frame: 60 days
|
Days of mechanical ventilation
|
60 days
|
ICU length of stay
Time Frame: 60 days
|
Days from ICU admission to discharge to wards
|
60 days
|
Mortality
Time Frame: 60 days
|
Rate of deceased patients in percentage
|
60 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of RT
Time Frame: 60 days
|
Total time of presence of RT
|
60 days
|
Phenotypes of RT
Time Frame: 60 days
|
Rate of the different phenotypes according to cycle initiation and termination of patient's respiratory effort
|
60 days
|
Intensity of breathing efforts
Time Frame: 60 days
|
Intensity of respiratory efforts as measured by esophageal manometry
|
60 days
|
Response to ventilatory adjustments
Time Frame: 60 days
|
Change in RT characteristics after changing ventilatory settings
|
60 days
|
Association with severity
Time Frame: 60 days
|
Association of RT with lung disease severity as measured by pO2:FiO2 ratio
|
60 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Miguel Ibarra Estrada, MD, Hospital Civil Fray Antonio Alcalde
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 260/22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France